+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ulcerative Colitis: KOL Insight

  • ID: 3114041
  • Report
  • FirstWord Publishing
1 of 3

FEATURED COMPANIES

  • Almirall
  • Atlantic Healthcare
  • Ferring
  • Genentech
  • InDex Pharmaceuticals
  • Isis Pharmaceuticals
  • MORE
The Ulcerative Colitis (UC) treatment market is already undergoing radical change as new, safer products that slow disease progression have come to market or will be launched in the next few years. While 5-ASA and corticosteroids will remain the backbone of treatment, new products that delay progression to steroid treatment or surgery are vying for market space.

Ulcerative Colitis: Dawn of the integrin inhibitors is a comprehensive report from FirstWord packed with the candid opinions of 12 leading North American and European KOLs that present business-critical insights for pharma. Get insights on what they think about current treatment options and the competing clinical and cost benefits that influence their decisions.

When and why will clinicians use these new therapies? Will Entyvio dominate as experience grows? Will the advantages of Genentech’s etrolizumab gate crash the market? Will naturally derived low toxicity LT-02 find favour with patients? When is combination therapy best, and in what circumstances? Ulcerative Colitis: Dawn of the integrin inhibitors answers these questions and more.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Almirall
  • Atlantic Healthcare
  • Ferring
  • Genentech
  • InDex Pharmaceuticals
  • Isis Pharmaceuticals
  • MORE
1.Executive summary
2.Research Objectives
3.Research Focus
4.Mild-to-moderate UC
4.1.Overview
4.2.Marketed Drugs
4.2.1.Uceris, Cortiment (Budesonide MMX; Cosmo/Santarus/Ferring)
4.3.Pipeline Drugs
4.3.1.LT 02 (phosphatidylcholine controlled-release; Dr Falk Pharma/Lipid Therapeutics)
5.Moderate-to-severe UC
5.1.Overview
5.2.Marketed Drugs
5.2.1.TNF inhibitors (Remicade, Humira, Simponi)
5.2.2.Entyvio (vedolizumab; Millennium/Takeda)
5.3.Pipeline Drugs
5.3.1.etrolizumab (Genentech/Roche)
5.3.2.tofacitinib ( Pfizer)
5.3.3.Kappaproct ( InDex Pharmaceuticals/Almirall)
5.3.4.alicaforsen ( Atlantic Healthcare/Isis Pharmaceuticals)
6.Current and future treatment algorithm
7.Conclusion
8.Appendix
8.1.KOL biographies
8.2.KOLs from North America
8.3.KOLs from Europe
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
-Genentech
-Roche
-InDex Pharmaceuticals
-Almirall
-Atlantic Healthcare
-Isis Pharmaceuticals
-Ferring
Note: Product cover images may vary from those shown
Adroll
adroll